Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. 2000

S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
HIV Neurobehavioral Research Center, University of California, San Diego, California 92103, USA. slentendre@ucsd.edu

Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir

Related Publications

S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
July 1993, The Journal of infectious diseases,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
July 2003, Antimicrobial agents and chemotherapy,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
September 1998, Neuroscience letters,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
January 1995, Current topics in microbiology and immunology,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
January 2000, Journal of the International Neuropsychological Society : JINS,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
January 1997, Lancet (London, England),
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
May 1998, The Journal of clinical psychiatry,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
June 2003, Antiviral therapy,
S L Letendre, and E V Capparelli, and R J Ellis, and J A McCutchan
August 2022, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!